Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018 Mar 3;7(5):e007570.
doi: 10.1161/JAHA.117.007570.

Safety of Perioperative Aprotinin Administration During Isolated Coronary Artery Bypass Graft Surgery: Insights From the ART (Arterial Revascularization Trial)

Collaborators, Affiliations
Observational Study

Safety of Perioperative Aprotinin Administration During Isolated Coronary Artery Bypass Graft Surgery: Insights From the ART (Arterial Revascularization Trial)

Umberto Benedetto et al. J Am Heart Assoc. .

Abstract

Background: There is still uncertainty about the safety of aprotinin for coronary artery bypass graft surgery. The ART (Arterial Revascularization Trial) was designed to compare survival after bilateral versus single internal thoracic artery grafting. Many of the ART patients (≈30%) received perioperative aprotinin. We investigated the association between perioperative aprotinin administration and short-term (in-hospital) and long-term outcomes by performing a post hoc analysis of the ART.

Methods and results: Among patients enrolled in the ART (n=3102) from 2004 to 2007, we excluded those who did not undergo surgery (n=18) and those with no information about use of perioperative aprotinin (n=9). Finally, 836 of 3076 patients (27%) received aprotinin. Propensity matching was used to select 536 pairs for final comparison. Aprotinin was also associated with an increased risk of hospital mortality (9 [1.7%] versus 1 [0.2%]; odds ratio, 9.12; 95% confidence interval [CI], 1.15-72.2; P=0.03), intra-aortic balloon pump insertion (37 [6.9%] versus 17 [3.2%]; odds ratio, 2.26; 95% CI, 1.26-4.07; P=0.006), and acute kidney injury (102 [19.0%] versus 76 [14.2%]; odds ratio, 1.42; 95% CI, 1.03-1.97; P=0.03). Aprotinin was not associated with a lower incidence of transfusion (37 [6.9%] versus 28 [5.2%]; odds ratio, 1.34; 95% CI, 0.81-2.23; P=0.25) and reexploration (26 [4.9%] versus 19 [3.5%]; hazard ratio, 1.39; 95% CI, 0.76-2.53; P=0.28). At 5 years, all-cause mortality was significantly increased in the aprotinin group (56 [10.6%] versus 38 [7.3%]; hazard ratio, 1.51; 95% CI, 1.0-2.28; P=0.045).

Conclusions: In the present post hoc ART analysis, aprotinin was associated with a significantly increased risk of early and late mortality.

Clinical trial registration: URL: http://www.isrctn.com. Unique identifier: ISRCTN46552265.

Keywords: Surgery; aprotinin; coronary artery bypass graft surgery; outcomes; propensity score matching.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mirrored histogram showing propensity score (PS) distribution in the 2 groups before (white) and after (red and blue) matching.
Figure 2
Figure 2
Five‐year cumulative incidence of all‐cause mortality in the matched groups.
Figure 3
Figure 3
Five‐year cumulative incidence of cardiovascular (CV) death, myocardial infarction (MI), cerebrovascular accident (CVA), and repeated revascularization in the matched groups.

Similar articles

Cited by

References

    1. Kuduvalli M, Oo AY, Newall N, Grayson AD, Jackson M, Desmond MJ, Fabri BM, Rashid A. Effect of peri‐operative red blood cell transfusion on 30‐day and 1‐year mortality following coronary artery bypass surgery. Eur J Cardiothorac Surg. 2005;27:592–598. - PubMed
    1. Mangano DT, Tudor IC, Dietzel C; Multicenter Study of Perioperative Ischemia Research Group, Ischemia Research and Education Foundation . The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354:353–365. - PubMed
    1. Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary artery bypass grafting and risk of death. N Engl J Med. 2008;358:771–783. - PubMed
    1. Shaw AD, Stafford‐Smith M, White WD, Phillips‐Bute B, Swaminathan M, Milano C, Welsby IJ, Aronson S, Mathew JP, Peterson ED, Newman MF. The effect of aprotinin on outcome after coronary‐artery bypass grafting. N Engl J Med. 2008;358:784–793. - PubMed
    1. Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussières JS, Côté D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R. A comparison of aprotinin and lysine analogues in high‐risk cardiac surgery. N Engl J Med. 2008;358:2319–2331. - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources